好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Cognitive Predictors of Quality of Life in Parkinson’s Disease: A Three-year Longitudinal Study
Movement Disorders
P4 - Poster Session 4 (11:45 AM-12:45 PM)
3-018
We sought to determine the cognitive markers associated with decreasing quality of life (QOL) in patients with Parkinson’s disease (PwP) over time with the aim to better assess meaningful cognitive performance and cognitive interventions in PwP in the future.
Parkinson’s disease (PD) is associated with worsened QOL over time. While cross-sectional studies show a relationship between cognitive functioning and QOL, few longitudinal studies exist investigating the relationship of cognitive performance with QOL in PwP.
We recruited PwP without dementia from a movement disorders clinic at an academic medical center. Participants were followed annually for three years, with motor and neuropsychological assessments at each visit. QOL was measured using the Parkinson’s Disease Questionnaire-39 (PDQ-39). We assessed cognitive performance, including Montreal Cognitive Assessment (MoCA) screening performance, verbal fluency via the Controlled Oral Word Association test (COWA), scanning/working memory via the Trail Making Test (specifically, Trails B-A) and immediate/delayed recall via the Hopkins Verbal Learning Test (HVLT). 好色先生 level, trial year, and level of depression, as measured via the Beck Depression Inventory II (BDI-II) were analyzed as potential confounders. Using random coefficient regression, we investigated the association between cognitive performance markers and changes in QOL in PwP over three years.
105 participants enrolled at baseline, and 67 patients completed three years of follow up. Mean PDQ-39 scores increased from 16.0 at baseline to 19.8 at year three. In multivariate analysis, worse trails B-A performance was uniquely associated with worsened QOL over time (p<0.001), while education level, COWA, MoCA, HTLV performance were not.

Deterioration in rote memory and executive function are associated with worsening quality of life over time in PwP, while worsened verbal fluency and recall are not. This study suggests that cognitive training targeting rote memory and executive function could be beneficial for improved QoL in PwP.
Authors/Disclosures
Katharine A. Henry, MD (UVA)
PRESENTER 		Dr. Henry has nothing to disclose.
Sara Trach No disclosure on file
Joseph Flanigan Joseph Flanigan has nothing to disclose.
James Patrie (University of Virginia) James Patrie has nothing to disclose.
Madaline B. Harrison, MD (UVA - Dept of Neurology) Dr. Harrison has nothing to disclose.
Matthew J. Barrett, MD, FAAN (Virginia Commonwealth University) The institution of Dr. Barrett has received research support from Kyowa Kirin. The institution of Dr. Barrett has received research support from NIH.
Binit Shah, MD, FAAN (University of Virginia) Dr. Shah has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Expert Institute.
Renzo Figari-Jordan, MD, FAAN (University of Virginia) Dr. Figari-Jordan has nothing to disclose.
M. Agustina Rossetti, PhD (University of Virginia Health System) Dr. Rossetti has nothing to disclose.
William A. Dalrymple, MD (University of Virginia Health System) Dr. Dalrymple has received personal compensation in the range of $500-$4,999 for serving as a Consultant for REACH. Dr. Dalrymple has received personal compensation in the range of $0-$499 for serving as a Consultant for M3. Dr. Dalrymple has received personal compensation in the range of $0-$499 for serving as a Consultant for Boxer Capital. Dr. Dalrymple has received personal compensation in the range of $0-$499 for serving as a Consultant for Capvision. Dr. Dalrymple has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Atheneum. Dr. Dalrymple has received personal compensation in the range of $0-$499 for serving as a Consultant for Cencora. Dr. Dalrymple has received personal compensation in the range of $0-$499 for serving as a Consultant for Lumanity. Dr. Dalrymple has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Huntington Study Group. Dr. Dalrymple has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Huntington Study Group. The institution of Dr. Dalrymple has received research support from Huntington's Disease Society of America.